Benralizumab

證據等級: L5

預測適應症: 5 個

Benralizumab: From Severe Eosinophilic Asthma to Dermatitis

One-Sentence Summary

Benralizumab is an anti-IL-5 receptor alpha (IL-5Rα) monoclonal antibody, originally approved for the add-on maintenance treatment of severe eosinophilic asthma. The TxGNN model predicts it may be effective for Dermatitis (ranked 2nd among 5 predicted indications), with 6 clinical trials and 20 publications available — however, the pivotal Phase 2 HILLIER trial demonstrated a lack of clinical effect, making this a cautionary example of model prediction contradicted by clinical evidence.

Quick Overview

Item	Content
Original Indication	Severe eosinophilic asthma (add-on maintenance treatment)
Predicted New Indication	Dermatitis (Rank 2); Thrombocytopenia due to immune destruction (Rank 1)
TxGNN Prediction Score (Rank 1)	99.34% (thrombocytopenia — no supporting evidence)
TxGNN Prediction Score (Rank 2)	99.16% (dermatitis — negative Phase 2 RCT)
Evidence Level	L2 (dermatitis: 1 completed Phase 2 RCT); L5 (all other indications)
Malaysia Market Status	✓ Marketed
Number of Registrations	1
Recommended Decision	Hold — Primary Phase 2 RCT produced definitive negative results

All Predicted Indications Overview

Rank	Predicted Indication	TxGNN Score	Evidence Level	Recommendation
1	Thrombocytopenia due to immune destruction	99.34%	L5	Hold
2	Dermatitis	99.16%	L2	Hold (negative RCT)
3	Acne keloid	99.13%	L5	Hold
4	Neonatal dermatomyositis	99.05%	L5	Hold
5	Amyopathic dermatomyositis	99.03%	L5	Hold

Note: Among the 5 TxGNN predictions, only dermatitis (Rank 2) has any clinical or literature evidence. The remaining 4 predictions rely solely on the model with zero supporting studies. This report focuses on dermatitis as the most informative indication for evaluation.

Why is This Prediction Reasonable?

Benralizumab is a humanised anti-IL-5Rα monoclonal antibody that depletes eosinophils and basophils through antibody-dependent cell-mediated cytotoxicity (ADCC). It was originally developed and approved for severe eosinophilic asthma, where eosinophil-driven inflammation plays a central pathogenic role. The TxGNN model assigned high scores to multiple immune-mediated conditions, likely reflecting the graph proximity between eosinophil-related disease nodes in the knowledge graph.

For dermatitis (specifically atopic dermatitis, AD), the mechanistic rationale is moderate but ultimately insufficient. Eosinophils are indeed present in AD skin lesions, and benralizumab has been shown to effectively deplete IL-5Rα-bearing cells in the skin of AD patients (PMID 40781582). However, the core driver of AD is the Th2-polarised IL-4/IL-13 axis, which leads to epidermal barrier disruption and the itch-scratch cycle. Eosinophil depletion alone does not interrupt this central pathogenic loop — a conclusion confirmed by the HILLIER trial’s negative results.

For thrombocytopenia due to immune destruction (Rank 1, highest TxGNN score), the mechanistic link is weak. ITP is driven by anti-platelet autoantibodies (anti-GPIIb/IIIa, anti-GPIb/IX) and T-cell-mediated platelet destruction. Eosinophils are not key players in ITP pathogenesis. The high TxGNN score likely reflects proximity of immune disease nodes in the knowledge graph rather than genuine therapeutic potential. The remaining predictions (acne keloid, neonatal dermatomyositis, amyopathic dermatomyositis) share similarly weak mechanistic rationales — the pathogenic drivers (fibroblast activation/TGF-β for keloids; type I interferon/complement for dermatomyositis) are unrelated to eosinophil biology.

Clinical Trial Evidence (Dermatitis)

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04605094	Phase 2	Terminated	194	HILLIER Study: Multinational, randomised, double-blind, placebo-controlled trial in moderate-to-severe AD. Terminated due to lack of efficacy. Published results (PMID 37178404) explicitly report “Lack of effect” of benralizumab on signs and symptoms of AD.
NCT03563066	Phase 2	Completed	20	Mechanistic study: Benralizumab successfully depleted IL-5Rα-bearing cells (eosinophils, basophils, ILC2s) in AD skin lesions, but this biological effect did not translate into clinical improvement.
NCT06734884	Phase 2	Not yet recruiting	96	Targets DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms), a distinct entity from typical AD. Eosinophils play a more prominent role in DRESS. Worth monitoring but not directly applicable to AD.
NCT06477653	Phase 2	Recruiting	30	Studies dupilumab (not benralizumab) as add-on for HES. Indirect relevance only.
NCT04126499	N/A	Completed	28	Observational retrospective study of benralizumab in severe eosinophilic asthma patients in Spain. Not designed for dermatitis evaluation.
NCT04763447	Phase 4	Recruiting	234	Studies omalizumab withdrawal in asthma. No direct relevance to benralizumab or dermatitis.

⚠️ Critical finding: The only two directly relevant trials (HILLIER and NCT03563066) both demonstrate that while benralizumab achieves its biological target (eosinophil depletion in skin), this does not result in clinical benefit for atopic dermatitis.

Clinical Trial Evidence (Other Predicted Indications)

Currently no related clinical trials registered for:

Thrombocytopenia due to immune destruction
Acne keloid
Neonatal dermatomyositis
Amyopathic dermatomyositis

Literature Evidence (Dermatitis)

PMID	Year	Type	Journal	Key Findings
37178404	2023	Phase 2 RCT	JEADV	HILLIER trial results: “Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis.” Definitive negative evidence.
38695680	2024	Phase 2 RCT (secondary)	Immunotherapy	Plain language summary of HILLIER trial, confirming benralizumab did not improve AD outcomes.
40781582	2025	Translational study	Clin Transl Allergy	Benralizumab depletes IL-5Rα-bearing cells in AD skin lesions, but biological effect does not correlate with clinical improvement.
39234416	2024	Translational study	JACI Global	Evaluated effect of benralizumab on skin inflammation after intradermal allergen challenge in AD patients.
39600395	2024	Review	Allergologie select	Comprehensive update on biologics for atopic diseases; contextualises benralizumab among other IL-5-targeting agents.
37201737	2023	Basic science review	Pharmacol Ther	Reviews pathogenic Th2 cells as therapeutic targets; explains why IL-4/IL-13 blockade (not IL-5Rα) is the effective pathway for AD.
36355314	2023	Review	Dermatol Ther	Discusses combination of dupilumab with other biologics; benralizumab mentioned in context of atopic comorbidities.
36270814	2023	Case report (AE)	Therapie	Adverse event report: Benralizumab-induced interstitial granulomatous dermatitis — a paradoxical skin reaction.
35987486	2022	Safety review	JACI In Practice	Safety of biologics (including benralizumab) for atopic diseases during pregnancy.
36411004	2023	Safety review	Immunol Allergy Clin N Am	Biologics for allergic rhinitis, asthma, and AD during pregnancy and lactation.

Malaysia Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
(Registration details pending)	Benralizumab	—	Severe eosinophilic asthma

The NPRA registry confirms 1 active registration. Detailed licence information (product name, dosage form, full indication text) was not available in the evidence pack at the time of this report.

Safety Considerations

Please refer to the package insert for safety information.

Note: Key warnings, contraindications, and drug interaction data were not available in the current evidence pack (Data Gap DG001). To proceed to safety evaluation (Stage S1), the package insert PDF should be obtained from the NPRA website and parsed for warnings, contraindications, and precautions.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite high TxGNN prediction scores (>99%) across all 5 predicted indications, the clinical evidence directly contradicts the most evidence-supported prediction. The HILLIER trial (Phase 2, n=194, randomised, double-blind, placebo-controlled) definitively showed lack of effect of benralizumab in moderate-to-severe atopic dermatitis. Translational studies confirmed that while benralizumab achieves its biological target (eosinophil depletion in skin), this does not translate into clinical improvement — demonstrating that eosinophils are not the rate-limiting pathogenic factor in AD. The remaining 4 predictions (thrombocytopenia, acne keloid, neonatal/amyopathic dermatomyositis) have zero supporting evidence and weak mechanistic rationale.

This case serves as an important validation example: a high TxGNN graph-proximity score does not guarantee therapeutic efficacy. The model likely assigned high scores based on the clustering of immune-mediated disease nodes, rather than capturing the specific mechanistic requirements of each disease.

To proceed, the following is needed:

❌ Dermatitis: No further development warranted — definitive negative Phase 2 evidence
⏸️ Thrombocytopenia (ITP): Requires preclinical evidence of eosinophil involvement in ITP pathogenesis before any clinical exploration can be justified
⏸️ Acne keloid / Dermatomyositis: Requires basic science establishing eosinophil/IL-5Rα role in pathogenesis
📋 General: Obtain NPRA package insert for complete safety profile (Data Gap DG001); obtain detailed MOA data from DrugBank (Data Gap DG002)
👁️ Monitor: NCT06734884 (benralizumab in DRESS) — if positive, may reopen discussion for eosinophil-driven dermatological conditions distinct from AD
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.